NEW YORK and MAINZ, GERMANY, November 4, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (BNTX) (Nasdaq: BNTX) today announced updated data from a Phase 2/3 clinical trial demonstrating a robust ...

We investigated county-level variation in mRNA COVID-19 vaccine use among Medicare beneficiaries throughout the United States. There was greater use of Pfizer-BioNTech vaccines than Moderna vaccines ...

Pfizer and BioNTech said Friday that the immune responses against Omicron BA.4/BA.5 subvariants were "substantially higher" in people who got its new bivalent booster compared with people who received ...

Nearly two years since the original coronavirus vaccines were given emergency authorization for use, we now have an updated vaccine that can be given as a booster shot. Here’s what we currently know ...

Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) is FDA-authorized under Emergency Use Authorization (EUA) for use in individuals 12 years of age and older as a single ...

BioNTech reported EUR 6.1 billion in revenue and EUR 3.2 billion in net profit in the third quarter, driven by BioNTech and partner Pfizer's sales of COVID-19 vaccine Comirnaty, and we're maintaining ...

(Reuters) – Pfizer Inc and BioNTech SE said on Thursday they are testing a third dose of their COVID-19 vaccine to better understand the immune response against new variants of the virus. They are ...

Video above: FDA votes to authorize more COVID-19 boosters, mix-and-matching doses in some casesA booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy — 95.6% — ...

Simultaneous administration of a COVID-19 mRNA booster shot and the seasonal influenza vaccine slightly increased the risk of systemic reactions during the following week compared with a booster shot ...

The US Food and Drug Administration on Thursday authorized the Pfizer/BioNTech Covid-19 vaccine for use as a booster in people ages 16 and 17. It's the first Covid-19 vaccine booster authorized for ...

Numbers from the CDC show nearly 67% of fully vaccinated people over the age of 65 have gotten a booster shot. Pfizer and BioNTech want the FDA to authorize yet another one for that age group. NPR ...